Ionis Pharmaceuticals Competitors
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts | Market Cap |
|---|---|---|---|---|---|---|---|---|
| PFE | Pfizer | Outperform |
2
|
$27.70 | $32.87 | 10.11% | 6 | $153.91B |
| AMGN | Amgen | Outperform |
4
|
$278.39 | $303.65 | 14.77% | 8 | $148.77B |
| SAN | Sanofi | Outperform |
16
|
91.90€ | 102.80€ | 18.61% | 9 | 116.22€B |
| REGN | Regeneron Pharmaceuticals | Outperform |
2
|
$937.61 | $961.26 | 11.99% | 8 | $101.15B |
| CSL | CSL | Outperform |
12
|
$275.39 | $205.51 | -26.23% | 5 | $132.65B |
| 4568 | Daiichi Sankyo Company | Buy |
4
|
¥5.50k | ¥5.24k | 5.42% | 0 | ¥10.23T |
| MRNA | Moderna | Outperform |
16
|
$125.59 | $135.42 | 0.96% | 1 | $42.68B |
| 4502 | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.13k | ¥4.74k | 10.30% | 0 | ¥6.50T |
| BIIB | Biogen | Outperform |
10
|
$213.51 | $299.62 | 35.12% | 13 | $31.47B |
| ALNY | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$150.31 | $245.24 | 43.70% | 7 | $18.96B |
| BMRN | BioMarin Pharmaceutical | Outperform |
10
|
$83.80 | $111.56 | 31.26% | 5 | $15.82B |
| SRPT | Sarepta Therapeutics | Outperform |
6
|
$130.63 | $158.66 | 26.69% | 6 | $12.37B |
| INCY | Incyte | Outperform |
9
|
$53.09 | $77.05 | 47.86% | 8 | $11.89B |
| EXEL | Exelixis | Outperform |
16
|
$22.12 | $26.44 | 22.06% | 5 | $6.44B |
| JAZZ | Jazz Pharmaceuticals | Outperform |
14
|
$109.29 | $188.32 | 71.56% | 4 | $6.88B |
| DYN | Dyne Therapeutics | Buy |
5
|
$26.00 | $28.13 | 40.38% | 0 | $2.24B |
| DCPH | Deciphera Pharmaceuticals | Outperform |
6
|
$25.38 | $23.40 | 0.87% | 4 | $2.08B |
| NTLA | Intellia Therapeutics | Outperform |
8
|
$23.27 | $75.84 | 200.82% | 21 | $2.06B |
| 4516 | Nippon Shinyaku | Outperform |
18
|
¥4.39k | ¥8.34k | 48.10% | 0 | ¥293.93B |
| BCRX | BioCryst Pharmaceuticals | Outperform |
7
|
$4.48 | $14.09 | 134.38% | 2 | $852.15M |
| PHARM | Pharming Group N.V. | Buy |
16
|
0.90€ | 1.85€ | 127.78% | 2 | 590.27€M |
| WVE | Wave Life Sciences | Outperform |
6
|
$5.88 | $9.21 | 129.59% | 3 | $602.86M |
| STOK | Stoke Therapeutics | Buy |
4
|
$11.69 | $19.33 | 79.64% | 3 | $574.86M |
| ABUS | Arbutus Biopharma | Outperform |
9
|
$2.68 | $6.34 | 102.61% | 0 | $491.88M |
| KALV | KalVista Pharmaceuticals | Buy |
7
|
$12.17 | $20.80 | 187.59% | 0 | $478.84M |
| FULC | Fulcrum Therapeutics | Outperform |
9
|
$7.65 | $10.21 | 89.54% | 7 | $443.16M |
| PYC | PYC Therapeutics | Buy |
8
|
$0.10 | $0.30 | 260.00% | 1 | $294.90M |